{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:40:20Z","timestamp":1786668020960,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T023791\/1"],"award-info":[{"award-number":["MR\/T023791\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbi.2025.106173","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:48:48Z","timestamp":1762274928000},"page":"106173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Developing interferon-\u03b2 as a safe in vivo experimental-medicine model of human inflammation"],"prefix":"10.1016","volume":"131","author":[{"given":"Eva","family":"Periche-Tomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"MacIver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Triantafilou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Szomolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbi.2025.106173_b0005","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1359105316659917","article-title":"A global measure of sickness behaviour: development of the Sickness Questionnaire","volume":"23","author":"Andreasson","year":"2018","journal-title":"J. Health Psychol."},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jir.2012.0167","article-title":"Immunomodulatory effects of interferons in malignancies","volume":"33","author":"Bekisz","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.bbi.2025.106173_b0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.bbi.2025.106173_b0020","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/CVI.05032-11","article-title":"Multisite comparison of high-sensitivity multiplex cytokine assays","volume":"18","author":"Breen","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/314873","article-title":"Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections","volume":"180","author":"Bruunsgaard","year":"1999","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.bbi.2025.106173_b0030","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2007.12.007","article-title":"Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans","volume":"63","author":"Brydon","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2025.106173_b0035","series-title":"Inflammation-Associated Depression: Evidence, Mechanisms and Implications","first-page":"31","article-title":"Role of inflammation in the development of neuropsychiatric symptom domains: evidence and mechanisms","author":"Capuron","year":"2017"},{"key":"10.1016\/j.bbi.2025.106173_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-\u03b1","volume":"56","author":"Capuron","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bbi.2025.106173_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1301362","article-title":"Basal ganglia hypermetabolism and symptoms of fatigue during interferon- \u03b1 therapy","volume":"32","author":"Capuron","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"16","key":"10.1016\/j.bbi.2025.106173_b0050","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1128\/JVI.76.16.8189-8199.2002","article-title":"Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro","volume":"76","author":"Castet","year":"2002","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2014.11.012","article-title":"IFN-\u03b2 inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis","volume":"64","author":"Cheng","year":"2015","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.bbi.2025.106173_b0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9343(02)01484-5","article-title":"Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly","volume":"114","author":"Cohen","year":"2003","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.1700725","article-title":"Brucella abortus triggers a cGAS-independent STING pathway to induce host protection that involves guanylate-binding proteins and inflammasome activation","volume":"200","author":"Costa Franco","year":"2018","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.neuron.2013.02.008","article-title":"Visceral influences on brain and behavior","volume":"77","author":"Critchley","year":"2013","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.iac.2009.02.002","article-title":"Cytokine, sickness behavior, and depression","volume":"29","author":"Dantzer","year":"2009","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.bbi.2025.106173_b0080","article-title":"Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms","author":"Davies","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"22","key":"10.1016\/j.bbi.2025.106173_b0085","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa","volume":"321","author":"Davis","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2025.106173_b0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bbi.2023.04.010","article-title":"Inflammation-induced reorientation of reward versus punishment sensitivity is attenuated by minocycline","volume":"111","author":"De Marco","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2025.106173_b0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbi.2021.10.005","article-title":"Diffusion-weighted MR spectroscopy (DW-MRS) is sensitive to LPS-induced changes in human glial morphometry: a preliminary study","volume":"99","author":"De Marco","year":"2022","journal-title":"Brain Behav. Immun."},{"issue":"9","key":"10.1016\/j.bbi.2025.106173_b0100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-\u03b2 signaling axis mediated via the receptor IFNAR1","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbi.2025.106173_b0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuroscience.2017.12.040","article-title":"Interferon-alpha-induced changes in NODDI predispose to the development of fatigue","volume":"403","author":"Dowell","year":"2019","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biopsych.2015.05.015","article-title":"Acute changes in striatal microstructure predict the development of interferon-Alpha induced fatigue","volume":"79","author":"Dowell","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.bbi.2025.106173_b0115","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0092-8674(00)00210-5","article-title":"TNF-\u03b1 induction by LPS is regulated posttranscriptionally via a Tpl2\/ERK-dependent pathway","volume":"103","author":"Dumitru","year":"2000","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bbi.2025.106173_b0120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.biopsych.2010.06.010","article-title":"Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward","volume":"68","author":"Eisenberger","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2025.106173_b0125","doi-asserted-by":"crossref","unstructured":"Exton, M. S., Baase, J., Pithan, V., Goebel, M. U., Limmroth, V., & Schedlowski, M.. 2002. Neuropsychological Performance and Mood States following Acute Interferon-\u00df-1b Administration in Healthy Males.","DOI":"10.1159\/000063671"},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","article-title":"Interferons in the treatment of multiple sclerosis","volume":"22","author":"Filipi","year":"2020","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.bbi.2025.106173_b0135","doi-asserted-by":"crossref","unstructured":"Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: A new immune\u2013metabolic viewpoint for age-related diseases. In Nature Reviews Endocrinology (Vol. 14). Nature Publishing Group. https:\/\/doi.org\/10.1038\/s41574-018-0059-4.","DOI":"10.1038\/s41574-018-0059-4"},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0895-7061(98)00252-0","article-title":"Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis","volume":"12","author":"Fukuhara","year":"1999","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00006199-198909000-00006","article-title":"Visual analogue scales: Measurement of subjective phenomena","volume":"38","author":"Gift","year":"1989","journal-title":"Nurs. Res."},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention Therapy Group","volume":"68","author":"Glue","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.07.004","article-title":"Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype","volume":"59","author":"Han","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","article-title":"Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity","volume":"66","author":"Harrison","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.biopsych.2009.03.007","article-title":"Neural origins of human sickness in interoceptive responses to inflammation","volume":"66","author":"Harrison","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0170","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/npp.2014.222","article-title":"Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants","volume":"40","author":"Harrison","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.bbi.2025.106173_b0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.biopsych.2014.01.005","article-title":"Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism","volume":"76","author":"Harrison","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biopsych.2015.07.018","article-title":"A neurocomputational account of how inflammation enhances sensitivity to punishments versus rewards","volume":"80","author":"Harrison","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"7590","key":"10.1016\/j.bbi.2025.106173_b0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"Nek7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2025.106173_b0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbi.2020.04.033","article-title":"Challenging the challenge: a randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development","volume":"88","author":"Hijma","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bcp.12968","article-title":"COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2weeks in healthy subjects","volume":"82","author":"Hu","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.bbi.2025.106173_b0205","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.bbi.2025.106173_b0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"issue":"4524","key":"10.1016\/j.bbi.2025.106173_b0215","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.6171035","article-title":"Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis","volume":"214","author":"Jacobs","year":"1981","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bbi.2025.106173_b0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archneur.1982.00510220007002","article-title":"Intrathecal interferon in multiple sclerosis","volume":"39","author":"Jacobs","year":"1982","journal-title":"Arch. Neurol."},{"issue":"8017","key":"10.1016\/j.bbi.2025.106173_b0225","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41586-024-07469-y","article-title":"A body\u2013brain circuit that regulates body inflammatory responses","volume":"630","author":"Jin","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/ni1569","article-title":"TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-\u03b2","volume":"9","author":"Kagan","year":"2008","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.bbi.2025.106173_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013852","article-title":"The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia","volume":"5","author":"Kale","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bbi.2025.106173_b0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acn3.84","article-title":"Immunomodulatory activity of interferon-beta","volume":"1","author":"Kasper","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.bbi.2025.106173_b0245","series-title":"Textbook of Immunopsychiatry","author":"Khandaker","year":"2021"},{"issue":"6","key":"10.1016\/j.bbi.2025.106173_b0250","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.bbi.2025.106173_b0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-021-01272-1","article-title":"Peripheral inflammation is associated with micro-structural and functional connectivity changes in depression-related brain networks","volume":"26","author":"Kitzbichler","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbi.2025.106173_b0260","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1212\/WNL.55.8.1231","article-title":"Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS","volume":"55","author":"K\u00fcmpfel","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0265","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jns.2012.12.001","article-title":"Longitudinal interferon-\u03b2 effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-\u03b3, IL-4 or IL-13","volume":"325","author":"Kvarnstr\u00f6m","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2016.191","article-title":"Lipopolysaccharide alters motivated behavior in a monetary reward task: a randomized trial","volume":"42","author":"Lasselin","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0275","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.bbi.2025.106173_b0280","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: Interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"21","key":"10.1016\/j.bbi.2025.106173_b0285","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon Alfa-2b Alone or in Combination with Ribavirin as initial Treatment for Chronic Hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2025.106173_b0290","unstructured":"McNair, D. M., Lorr, M., & Droppleman, L. F., 1971. Manual profile of mood states."},{"key":"10.1016\/j.bbi.2025.106173_b0295","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bbi.2025.01.002","article-title":"Advancing precision psychiatry and targeted treatments: insights from immunopsychiatry","volume":"125","author":"Miller","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"7","key":"10.1016\/j.bbi.2025.106173_b0300","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.intimp.2009.03.004","article-title":"Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis","volume":"9","author":"Mirandola","year":"2009","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2249.2000.01175.x","article-title":"Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-\u03b1)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-\u03b2) treatment","volume":"120","author":"\u00d6zenci","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbi.2025.106173_b0310","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-4933-9-15","article-title":"Hallmarks of human \u2018immunosenescence\u2019: adaptation or dysregulation?","volume":"9","author":"Pawelec","year":"2012","journal-title":"Immunity and Ageing"},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0315","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s13277-014-2669-3","article-title":"Treatment-related fatigue with everolimus and temsirolimus in patients with cancer\u2014a meta-analysis of clinical trials","volume":"36","author":"Peng","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bbi.2025.106173_b0320","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbi.2024.09.038","article-title":"Acute effects of interferon-alpha on cellular anabolic and catabolic processes are associated with the development of fatigue during Interferon-alpha-based therapy for Hepatitis-C: a preliminary study","volume":"123","author":"Periche-Tomas","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2025.106173_b0325","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bbi.2021.04.004","article-title":"Human in vivo neuroimaging to detect reprogramming of the cerebral immune response following repeated systemic inflammation","volume":"95","author":"Peters van Ton","year":"2021","journal-title":"Brain Behav. Immun."},{"issue":"5396","key":"10.1016\/j.bbi.2025.106173_b0330","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0335","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2377-11-26","article-title":"Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?","volume":"11","author":"Prosperini","year":"2011","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0340","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.biopsych.2008.08.010","article-title":"Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression","volume":"65","author":"Raison","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0345","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41467-017-01687-x","article-title":"TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells","volume":"8","author":"Saitoh","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbi.2025.106173_b0350","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/jir.1996.16.759","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human interferon-\u03b2 in healthy male volunteers","volume":"16","author":"Salmon","year":"1996","journal-title":"J. Interferon Cytokine Res."},{"issue":"8","key":"10.1016\/j.bbi.2025.106173_b0355","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","article-title":"Neuromodulation by the immune system: a focus on cytokines","volume":"21","author":"Salvador","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"40","key":"10.1016\/j.bbi.2025.106173_b0360","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.1073\/pnas.1511003112","article-title":"Imaging robust microglial activation after lipopolysaccharide administration in humans with PET","volume":"112","author":"Sandiego","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bbi.2025.106173_b0365","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1189\/jlb.2A0414-191R","article-title":"An essential role for IFN-\u03b2 in the induction of IFN-stimulated gene expression by LPS in macrophages","volume":"96","author":"Sheikh","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bbi.2025.106173_b0375","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1053\/j.gastro.2010.01.051","article-title":"Interferon-\u03b1\u2013induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection","volume":"138","author":"Stegmann","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bbi.2025.106173_b0380","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"Storey","year":"2002","journal-title":"J. R. Stat. Soc. Ser. B Stat Methodol."},{"issue":"1 Suppl 1","key":"10.1016\/j.bbi.2025.106173_b0385","first-page":"23","article-title":"The effects of interferon-alpha on the production and action of other cytokines","volume":"25","author":"Taylor","year":"1998","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.bbi.2025.106173_b0390","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.4049\/jimmunol.177.6.3542","article-title":"IFN-\u03b2 inhibits T cell activation capacity of central nervous system APCs","volume":"177","author":"Teige","year":"2006","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.bbi.2025.106173_b0395","doi-asserted-by":"crossref","first-page":"15319","DOI":"10.1074\/jbc.R700009200","article-title":"Toll-like receptors and type I interferons*","volume":"282","author":"Uematsu","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.bbi.2025.106173_b0400","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1001\/archinte.162.20.2333","article-title":"Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study","volume":"162","author":"Walston","year":"2002","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0361-9230(94)90179-1","article-title":"Neural and biochemical mediators of endotoxin and stress-induced c-fos expression in the rat brain","volume":"34","author":"Wan","year":"1994","journal-title":"Brain Res. Bull."},{"issue":"7","key":"10.1016\/j.bbi.2025.106173_b0410","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1128\/JVI.77.7.3898-3912.2003","article-title":"Alpha Interferon Induces Distinct Translational Control Programs to Suppress Hepatitis C Virus RNA Replication","volume":"77","author":"Wang","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.bbi.2025.106173_b0415","series-title":"The Neuroimmunological Basis of Behavior and Mental Disorders","first-page":"71","article-title":"Interferon-\u03b1, molecular signaling pathways and behavior","author":"Wang","year":"2009"},{"issue":"13","key":"10.1016\/j.bbi.2025.106173_b0420","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1128\/JVI.79.13.8295-8302.2005","article-title":"Innate STAT1-dependent genomic response of neurons to the antiviral cytokine alpha interferon","volume":"79","author":"Wang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bbi.2025.106173_b0425","article-title":"Systemic interferon-a regulates interferon-stimulated genes in the central nervous system","volume":"9","author":"Wang","year":"2008","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bbi.2025.106173_b0430","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1089\/jir.1998.18.967","article-title":"Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX","volume":"18","author":"Williams","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.bbi.2025.106173_b0435","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1084\/jem.182.6.1985","article-title":"Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions","volume":"182","author":"Windhagen","year":"1995","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bbi.2025.106173_b0440","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41591-024-03309-8","article-title":"Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction","volume":"31","author":"Wood","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbi.2025.106173_b0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/147323000503300306","article-title":"Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis","volume":"33","author":"Wroe","year":"2005","journal-title":"J. Int. Med. Res."},{"issue":"2","key":"10.1016\/j.bbi.2025.106173_b0450","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbi.2010.10.015","article-title":"Immune modulation of learning, memory, neural plasticity and neurogenesis","volume":"25","author":"Yirmiya","year":"2011","journal-title":"Brain Behav. Immun."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159125004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159125004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:09:28Z","timestamp":1766074168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159125004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":90,"alternative-id":["S0889159125004155"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2025.106173","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing interferon-\u03b2 as a safe in vivo experimental-medicine model of human inflammation","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2025.106173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106173"}}